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Steatohepatitis is a cause of hepatocellular carcinoma development; however, the underlying mechanisms
are poorly defined. In this issue of Cancer Cell, Nakagawa and colleagues demonstrate that activation of
endoplasmic reticulum stress signaling is instrumental in the development of steatohepatitis and synergizes
with proinflammatory pathways to promote hepatocarcinogenesis.Over the past two decades, the rising inci-
dence of hepatocellular carcinoma (HCC)
has paralleled an increased prevalence of
obesity, suggesting that the two may be
linked. Indeed, obesity fuels the produc-
tion of proinflammatory cytokines leading
to the accumulation of free fatty acids in
hepatocytes, a condition termed steato-
hepatitis (Starley et al., 2010). This pathol-
ogy leads to chronic inflammation which,
in turn, induces nonalcoholic steatohepa-
titis (NASH), a risk factor in the promotion
of HCC. Activation of endoplasmic reticu-
lum (ER) stress has been clearly shown to
contribute to liver steatosis, steatohepati-
tis, and NASH (Starley et al., 2010). How-
ever, the role of ER stress signaling in the
development and progression of HCC is
much less documented. Recent reports
linking the unfolded protein response
(UPR) to inflammation (Garg et al., 2012)
suggest a tightly interconnected network
that could certainly be involved in liver
carcinogenesis. In this issue of Cancer
Cell, Nakagawa et al. (2014) report a novel
mechanism of carcinogenesis in which
the activation of ER stress signals plays
a synergistic role with high fat diet
(HFD)-induced steatohepatitis to promote
the development of HCC (Figure 1).
Nakagawa et al. (2014) utilized the ma-
jor urinary protein-urokinase plasminogen
activator (MUP-uPA) transgenic mouse
model to study ER stress in hepatocytes.
TheMUP-uPA transgene induces overex-
pression of the uPA protein, which accu-
mulates in the hepatocyte ER, thereby
leading to ER stress and liver lesions inmice. Remarkably, the MUP-uPA mice
fed with a HFD exhibited greater liver
damage, immune infiltration, and in-
creased lipogenesis compared to their
control low fat diet counterparts. MUP-
uPA mice on HFD rapidly displayed pa-
thology indicative of NASH that evolved
into HCC over time. It has been reported
that the major NASH-promoting effects
of ER stress increase lipogenesis through
SREBP activation (Kammoun et al., 2009),
oxidative stress, and susceptibility to lipo-
toxic cell death. Moreover, Nakagawa
et al. (2014) indicate that in normal hepa-
tocytes both steatohepatitis and HCC
development are independent of CHOP,
thereby ruling out the involvement of this
apoptosis promoting transcription factor
in MUP-uPA and HFD-induced hepato-
cyte cell death. Interestingly, the role of
ATF6, a major ER stress activated tran-
scription factor likely to be involved in
HCC development (Shuda et al., 2003),
remains to be investigated in the authors’
experimental model.
HCC takes several decades to appear
and evolves from premalignant lesions in
chronically damaged livers that create
the bedding for HCC progenitor cells
(HcPCs). The ability of HcPCs to progress
into HCC depends on autocrine inter-
leukin 6 production. To investigate the
involvement of tumor necrosis factor
(TNF) signaling in hepatocarcinogenesis,
Nakagawa et al. (2014) transplanted
HcPCs from diethylnitrosamine-treated
wild-type, Tnfr1/, or IkbkbDhep into
MUP-uPAmice. They found tumor growthCancer Cell 26, Sto be abrogated in HFD-fed mice trans-
planted with either Tnfr1/ or IkbkbDhep-
HcPCs compared to those transplanted
with wild-type HcPCs, thus demon-
strating the major role of TNF and IkB
kinase b signaling in hepatocarcinogene-
sis in HFD-fed mice.
The contribution of ER stress to HCC
has been proposed repeatedly in the
context of sensitivity to the chemothera-
peutic agent sorafenib (Yi et al., 2012),
its involvement in hepatocarcinogenesis
(Shuda et al., 2003), or, more recently,
the presence of somatic mutations in
genes coding for components of the
UPR or the ER homeostasis control ma-
chinery (Guichard et al., 2012). However,
thus far, no connection has been made
between ER stress signaling and steato-
hepatitis-induced HCC. The work of
Nakagawa et al. (2014) suggests that
several mechanisms related to ER stress
and hypernutrition could cooperate to
induce HCC development. These poten-
tial mechanisms could occur through: (1)
HFD-induced hepatosteatosis, resulting
in mild ER stress in MUP-uPA mice due
to uPA expression; (2) ER stress-induced
SREBP1 activation in MUP-uPA mice,
thereby enhancing lipogenesis and
increasing the degree of hepatic steatosis
beyond that achieved by HFD alone; (3)
increased reactive oxygen species pro-
duction by ER stress and steatosis in
hepatocytes aswell as subsequent oxida-
tive stress and its genotoxic conse-
quences (Figure 1); (4) ER and oxidative
stress-mediated increase in hepatocyteseptember 8, 2014 ª2014 Elsevier Inc. 301
Figure 1. ER Stress in Steatohepatitis-Induced Hepatocarcinogenesis
(A) Schematic timeline of HCC progression as reported by Nakagawa et al. (2014). MUP-uPA mice,
although exhibiting ER stress in the liver, did not develop HCC, whereas signs of steatosis and weak
fibrosis can be observed. On HFD, C57BL/6 mice developed steatosis, steatohepatitis, and HCC (in a
TNFR1-dependent manner) over a period of 40 weeks. Finally, HFD applied to MUP-uPA mice led to a
more penetrant HCC phenotype than in wild-type animals, thus demonstrating the synergistic impact of
combined ER stress and HFD on HCC development.
(B) Qualitative representation of the intensity of ER stress observed in the models studied by Nakagawa
et al. (2014). MUP-uPA mice presented a strong basal ER stress, which dissipated over time with hepa-
tocyte renewal. In contrast, HFD-induced ER stress increases with time. Finally, HFD in MUP-uPA mice
led to prolonged and reinforced ER stress throughout the experimental pipeline, thus correlating ER stress
intensity with HCC outcome.
(C) Qualitative representation of the relevance of ER stress signaling components toward HCC develop-
ment upon HFD. The IRE1 arm of the UPR appears to play a significant role in steatosis-induced HCC,
because the phosphorylation of IRE1 and the activation of JNK are increased and 25% of RIDD targets
impact lipid metabolism (although RIDD was not investigated by Nakagawa et al., 2014). The latter is
also a direct target of TNF signaling through TNFR1 and thus represents a point of convergence of two
of the signaling pathways involved in hepatocarcinogenesis. The activation of SREBP1 also represents
an important factor activated upon ER stress that stimulates lipogenesis and enhances the steatotic/stea-
tohepatitic phenotype. Interestingly, the phosphorylation of eIF2a is also observed and relevant, but it
might also be due to the activation of the integrated stress response, a key player in metabolic syndrome.
Finally, both CHOP and XBP1s appear dispensable for steatohepatitis-induced HCC development. The
respective roles of ATF4 and ATF6 remain to be investigated (dotted bars).
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Previewssensitivity to lipotoxicity and cell death,
thereby releasing inflammatory mediators
that attract and activate immune cells; (5)
the production of TNF and other media-
tors by activated inflammatory macro-
phages, which stimulate compensatory
hepatocyte proliferation and expand
HCC progenitors; and/or (6) a global
change in ER stress activation kinetics
and intensities, which could lead to hepa-
tocyte transformation via poorly defined
mechanisms (Figure 1).
HCC is extremely difficult to treat and
is the third leading cause of deaths asso-302 Cancer Cell 26, September 8, 2014 ª201ciated with cancers worldwide. The cur-
rent treatments are liver resection and
liver transplantation, but few HCC pa-
tients can benefit from surgery because
most are diagnosed at late stages. Sora-
fenib is currently the only drug available
for HCC and increases survival time by
approximately 3 months. In their article,
Nakagawa et al. (2014) discuss the pos-
sibility of therapeutic intervention through
the combined action of anti-TNF therapy
and chemical chaperones. As such, the
use of chemical chaperones (4-phenyl
butyrate or tauroursodeoxycholic acid)4 Elsevier Inc.has been applied to animal models to
resolve liver steatosis and steatohepatitis
(Ben Mosbah et al., 2010). This might
indeed be efficient for decreasing the
steatohepatitis burden, which would in
turn be anticipated to reduce the occur-
rence of HCC. However, the window in
which this type of treatment should be
applied is still questionable. Indeed, the
steatohepatitis/NASH status is not easily
diagnosed to allow preventive HCC
treatment. Later, at the HCC stage, the
use of anti-TNF therapy could reduce
the inflammation of the tumor bed. How-
ever, one might expect that chemical
chaperones may not be the best thera-
peutic option for tumor cells, because
they might actually increase proteostasis
and confer proliferative advantages.
Alternatively, one could combine anti-
TNF therapy and inhibitors of ER stress
downstream of the UPR (Hetz et al.,
2013). Although, Nakagawa et al. (2014)
have shown that XBP1 is not instru-
mental in NASH development in MUP-
uPA mice, approximately a quarter of
the validated regulated IRE1-dependent
mRNA decay of RNA (RIDD) substrates
are associated with lipid metabolism
(Maurel et al., 2014). Therefore, it would
be interesting to investigate the activa-
tion status of RIDD in the target hepato-
cytes because such molecules, and in
particular IRE1 inhibitors, were shown
to be potentially highly relevant anti-
cancer molecules. Their use would not
only be expected to reduce hepatocyte
damage, inflammation, and steatosis,
but would also slow down tumor growth,
because these molecules may exert ef-
fects on both the tumor and adjacent
parenchyma.ACKNOWLEDGMENTS
We thank Dr. Susan E. Logue for critically reading
the manuscript. Our research is supported by
grants from Institut National du Cancer, La Ligue
contre le Cancer, and Belgian grant-Interuniversity
Attraction Poles, IAP 7/32.REFERENCES
Ben Mosbah, I., Alfany-Ferna´ndez, I., Martel, C.,
Zaouali, M.A., Bintanel-Morcillo, M., Rimola, A.,
Rode´s, J., Brenner, C., Rosello´-Catafau, J., and
Peralta, C. (2010). Cell Death Dis. 1, e52.
Garg, A.D., Kaczmarek, A., Krysko, O., Vandena-
beele, P., Krysko, D.V., and Agostinis, P. (2012).
Trends Mol. Med. 18, 589–598.
Cancer Cell
PreviewsGuichard, C., Amaddeo, G., Imbeaud, S., Ladeiro,
Y., Pelletier, L., Maad, I.B., Calderaro, J., Bioulac-
Sage, P., Letexier, M., Degos, F., et al. (2012).
Nat. Genet. 44, 694–698.
Hetz, C., Chevet, E., and Harding, H.P. (2013). Nat.
Rev. Drug Discov. 12, 703–719.
Kammoun, H.L., Chabanon, H., Hainault, I., Lu-
quet, S., Magnan, C., Koike, T., Ferre´, P., and Fou-
felle, F. (2009). J. Clin. Invest. 119, 1201–1215.Maurel, M., Chevet, E., Tavernier, J., and Gerlo, S.
(2014). Trends Biochem. Sci. 39, 245–254.
Nakagawa, H., Umemura, A., Taniguchi, K., Font-
Burgada, J., Dhar, D., Ogata, H., Zhong, Z., Vala-
sek, M.A., Seki, E., Hidalgo, J., et al. (2014). Cancer
Cell 26, this issue, 331–343.
Shuda, M., Kondoh, N., Imazeki, N., Tanaka, K.,
Okada, T., Mori, K., Hada, A., Arai, M., Wakatsuki,Cancer Cell 26, ST., Matsubara, O., et al. (2003). J. Hepatol. 38,
605–614.
Starley, B.Q., Calcagno, C.J., and Harrison, S.A.
(2010). Hepatology 51, 1820–1832.
Yi, P., Higa, A., Taouji, S., Bexiga, M.G., Marza, E.,
Arma, D., Castain, C., Le Bail, B., Simpson, J.C.,
Rosenbaum, J., et al. (2012). Mol. Cancer Ther.
11, 2610–2620.FAL1ing inside an AmpliconAlejandro Athie1 and Maite Huarte1,*
1Center for Applied Medical Research, University of Navarra, 331008 Pamplona, Spain
*Correspondence: maitehuarte@unav.es
http://dx.doi.org/10.1016/j.ccr.2014.08.009
Frequently amplified regions of the cancer genome contain well-known oncogenes. In this issue of Cancer
Cell, Hu and colleagues discover that FAL1, a long noncoding RNA is encoded in one of these regions.
FAL1 acts as an oncogene by stabilizing BMI1, which results in the repression of CDKN1A expression.Genomic instability in cancer leads to
rearrangements, amplifications, and de-
letions of entire DNA fragments. Somatic
copy-number alterations (SCNAs) pro-
vide a mechanism for modifying the
gene dose to confer selective advantage
for tumor cells. The amplification of a
gene can lead to its overexpression:
well-known oncogenes such as EGFR,
ERBB2, and MYC are contained in
frequently-amplified regions (Beroukhim
et al., 2010).
Amplicon length can vary from several
kilobases to megabases, often contain-
ing many genes. A big challenge for
cancer biology is to identify which of
the genes contained in an amplified
region play a causal role in carcino-
genesis. The challenge is even greater
if we take a closer look and consider
not only the protein-coding genes but
also the long noncoding RNAs (lncRNAs)
present in these amplified regions.
Although growing evidence relates some
lncRNAs with cancer progression, the
function of the vast majority of lncRNAs
remains to be determined, complicating
the task.
In this issue of Cancer Cell, Hu et al.
(2014) rise to this challenge by focusing
their study on the noncoding portion of
the genome to identify lncRNAs that areclinically relevant to cancer. They show
that a large number of lncRNAs are inside
somatic copy number alterations. Some
of these altered regions do not contain
any previously identified cancer-associ-
ated protein-coding genes, suggesting
that the noncoding genes could be
responsible for driving the disease. These
analyses reveal a set of noncoding candi-
date cancer drivers and highlight the po-
tential role of lncRNAs in the development
of cancer.
By integrating SNP arrays of 2,394
tumors of 12 cancer types with gene
expression microarrays of 40 cancer cell
lines, Hu et al. (2014) identify a set of ex-
pressed lncRNAs frequently amplified in
tumors in the study. From this set, the au-
thors explore in depth the role of a novel
lncRNA and putative oncogene named
focally amplified lncRNA on chromosome
1 or FAL1.
More detailed analysis of FAL1 copy
number gain showed that this alteration
was frequently present in epithelial
tumors. Interestingly, the high level of
FAL1 expression is not always associated
with its focal amplification, suggesting
that other mechanisms may contribute
to its increased expression in cancer
cells. Further analysis using an ovarian
cancer tumor cohort revealed a higherexpression of FAL1 in late-stage tumors
and an association between the genomic
amplification of FAL1 and decreased pa-
tient survival.
Besides the strong genetic evidence
provided by the SCNA analysis, FAL1
displayed oncogenic features in several
functional experiments. Overexpression
of FAL1 resulted in an increase in the
colony-formation capacity of cells, an
effect enhanced by the additional over-
expression of MYC or mutant RAS.
These experiments not only indicate
that FAL1 can act in cooperation with
other oncogenes, but also suggest that
the lncRNA exerts its functions in trans.
In fact, downregulation of FAL1 by short
hairpin RNAs showed no effect on the
expression levels of other genes present
in the amplicon. Interestingly, among
these genes is MCL1, a known protein-
coding oncogene (Beroukhim et al.,
2010). However, alteration of FAL1 levels
had no effect on MCL1, suggesting an
independent role. Similar to FAL1, the
oncogenic lncRNA PCAT-1 has been
recently shown to appear coamplified
with an oncogene (MYC in this case),
while it functions independently of its
neighboring oncogene, i.e., via a MYC-
independent mechanism (Prensner et al.,
2011). In contrast, a recent study (Tsengeptember 8, 2014 ª2014 Elsevier Inc. 303
